D-Trp-Aib Peptide Inhibits Amyloid Toxicity in Glaucoma
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for glaucoma primarily focus on lowering intraocular pressure, but fail to address the progressive degeneration of retinal ganglion cells, and existing agents like Congo red and Aβ antibodies are toxic or impractical for human use.
Innovation Solution
Development of short chain peptides with aromatic amino acids that inhibit β-amyloid formation, which can be administered effectively as eye drops or orally, combining with other pharmaceutical agents to treat glaucoma and related ocular disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If Congo red or Aβ antibodies are used to inhibit Aβ aggregation, then glaucomatous degeneration of retinal ganglion cells is reduced, but the agents are toxic or impractical for human use
Solution Approach 1:
The patent replaces expensive, toxic long-term therapies (Congo red, antibodies) with short peptides that are chemically synthesized, inexpensive to produce, and can be administered repeatedly without cumulative toxicity. The peptides are designed to be stable enough for therapeutic use but not persistent enough to cause long-term accumulation issues.
Solution Approach 2:
The patent modifies the chemical structure parameters of Aβ-binding molecules by using short peptide sequences with specific amino acid compositions (rich in aromatic and hydrophobic residues) rather than large protein structures. This structural parameter change reduces molecular weight, improves penetration, and eliminates immunogenicity while maintaining Aβ-binding capability.
2Stress or pressure
If current glaucoma medications are used to lower intraocular pressure, then IOP is reduced, but progressive degeneration of retinal ganglion cells is not addressed
Solution Approach 1:
The patent creates a therapeutic agent that performs multiple functions: it binds to Aβ peptides to prevent their toxic aggregation, it penetrates the blood-retina barrier to reach retinal ganglion cells, and it provides neuroprotective effects. This multi-functionality addresses both the amyloid hypothesis and neurodegeneration aspects of glaucoma simultaneously.
Solution Approach 2:
The short peptides act as intermediaries between the harmful Aβ peptides and the retinal ganglion cells. They bind to Aβ oligomers, neutralizing their toxicity, and facilitate the clearance or inactivation of these toxic species, thereby protecting neurons without directly interacting with them.
3Reliability
If short chain peptides with aromatic amino acids are used to inhibit β-amyloid formation, then Aβ toxicity is blocked, but the complexity of peptide synthesis and formulation increases
Solution Approach 1:
The patent divides the complex task of Aβ inhibition into manageable peptide segments of 2-20 amino acids. These short sequences can be synthesized using standard solid-phase peptide synthesis methods, purified by HPLC, and formulated into stable pharmaceutical compositions, making the overall process tractable despite the complexity of targeting Aβ pathology.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These peptides demonstrate therapeutic efficacy in preventing and treating glaucoma by inhibiting β-amyloid toxicity, are well-tolerated, and can be used at various administration frequencies, offering a dual mechanism of action as β-sheet breakers and oligomerization inhibitors.
Implementation Method 1
inhibiting Aβ formation and/or occurrence of said Aβ, which is effective for alleviation of the condition
Implementation Method 2
offering a dual mechanism of action as β-sheet breakers and oligomerization inhibitors
Data Source
AI summary
Methods for the prevention and treatment of ocular disorders, in particular glaucoma, through blocking the toxic effects of β-amyloid (Aβ) derivatives, and pharmaceutical compositions for effecting such prevention and treatment thereof.